Product
TADIOS
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Multicenter, Double-blind, Placebo-controlled, Maximum 10 Days Administration Study to Evaluate the Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2022-02-24